I’m sad to report that the Data and Safety Monitoring Board (DSMB) for the Clinical Trial of Ceftriaxone in Subjects with ALS has recommended that the trial be stopped immediately because the study was unlikely to reach the pre-determined efficacy criteria. Leadership from the National Institute of Neurological Disorders and Stroke (NINDS) concurred.
If you remember from previous posts (1, 2, 3, 4), this was the clinical trial that I have been participating in since June 7, 2010; less than a month after diagnosis. Needless to say, this was not the outcome I was hoping for! Still, I’m confident that this trial and all of its dedicated participants have helped move ALS research forward.